Immunogenicity of the 9-valent human papillomavirus vaccine: Post hoc analysis from five phase 3 studies
Human Vaccines & Immunotherapeutics · 2025
DOI: 10.1080/21645515.2024.2425146 ↗Kurz gefasst
Klinische Studie (Phase III) in der Zeitschrift Human Vaccines & Immunotherapeutics, 2025. Verfasst von Anna R Giuliano und 15 weiteren Autor:innen. Beteiligte Einrichtung: Center for Immunization and Infection Research in Cancer, Moffitt Cancer Center and Research Institute, Tampa, FL, USA. Hauptthemen laut MEDLINE: Antibodies, Viral, Immunogenicity, Vaccine, Papillomavirus Infections, Papillomavirus Vaccines. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Merck Sharp & Dohme Corp LLC.
Abstract (Originalsprache)
Post hoc analyses of 9-valent human papillomavirus (9vHPV) vaccine immunogenicity were conducted in five Phase 3 studies that enrolled males. Month 7 antibody geometric mean titers (GMTs) after three 9vHPV vaccine doses were analyzed in 10,024 males/females aged 16-26 years from studies 001 (NCT00543543), 002 (NCT00943722), 003 (NCT01651949), and 020 (NCT02114385). Covariates considered were age, gender, sexual orientation, region of residence, and race. GMTs among 2599 males/females aged 9-15 years (studies 002 and 010 [NCT01984697]) were assessed 6 months after one, two, and three 9vHPV vaccine doses. 9vHPV vaccine immunogenicity was robust across populations. Month 7 GMTs were generally higher in participants aged 16-21 versus 22-26 years. Region and race minimally impacted immunogenicity. Adjusted integrated analysis showed lower immunogenicity in men who have sex with men (MSM) versus heterosexual men (HM) for nine HPV types, and higher immunogenicity in HM versus females for seven HPV types. Among 9-15-year-olds, trends toward higher GMTs in males versus females post-Dose 3, similar GMTs post-Dose 2, and lower post-Dose 1 were observed. In conclusion, 9vHPV vaccine immunogenicity was robust in males aged 16-26 years across a range of baseline characteristics. GMT ratios for males versus females aged 9-15 years tended to increase with more doses.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Center for Immunization and Infection Research in Cancer, Moffitt Cancer Center and Research Institute, Tampa, FL, USA.
- Department of Medicine, University of California at San Francisco, San Francisco, CA, USA.
- Department of Surgery, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
- Department of Obstetrics and Gynecology, Galilee Medical Center and Azrieli Faculty of Medicine, Bar-Ilan University, Nahariya, Israel.
- Centre for the Evaluation of Vaccination, Vaccine & Infectious Disease Institute (VAXINFECTIO), Faculty of Medicine and Health Sciences, University of Antwerp, Antwerp, Belgium.
- Research Unit, Pablo Tobon Uribe Hospital, Medellin, Antioquia, Colombia.
ORCID-Profile: Anna R Giuliano
Förderung
- Merck Sharp & Dohme Corp LLC
Zitieren
APA
Giuliano, A. R., Palefsky, J. M., Goldstone, S. E., Bornstein, J., De Coster, I., Guevara, A. M., Mogensen, O., Schilling, A., Van Damme, P., Vandermeulen, C., Ellison, M. C., Thomas Group, Kaplan, S., Lin, J., Bonawitz, R., & Luxembourg, A. (2025). Immunogenicity of the 9-valent human papillomavirus vaccine: Post hoc analysis from five phase 3 studies. Human Vaccines & Immunotherapeutics. https://doi.org/10.1080/21645515.2024.2425146
Vancouver
Giuliano AR, Palefsky JM, Goldstone SE, Bornstein J, De Coster I, Guevara AM, et al. Immunogenicity of the 9-valent human papillomavirus vaccine: Post hoc analysis from five phase 3 studies. Human Vaccines & Immunotherapeutics. 2025. doi:10.1080/21645515.2024.2425146
BibTeX
@article{Giuliano2025,
author = {Giuliano, Anna R and Palefsky, Joel M and Goldstone, Stephen E and Bornstein, Jacob and De Coster, Ilse and Guevara, Ana María and Mogensen, Ole and Schilling, Andrea and Van Damme, Pierre and Vandermeulen, Corinne and Ellison, Misoo C and Thomas Group, Thomas Group and Kaplan, Susan and Lin, Jianxin and Bonawitz, Rachael and Luxembourg, Alain},
title = {Immunogenicity of the 9-valent human papillomavirus vaccine: Post hoc analysis from five phase 3 studies},
journal = {Human Vaccines & Immunotherapeutics},
year = {2025},
doi = {10.1080/21645515.2024.2425146}
}
EUVIMED